vs
AIR LEASE CORP（AL）与Apellis Pharmaceuticals, Inc.（APLS）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是AIR LEASE CORP的1.4倍（$199.9M vs $140.8M），AIR LEASE CORP净利率更高（128.5% vs -29.5%，领先158.0%），AIR LEASE CORP同比增速更快（90.4% vs -5.9%），AIR LEASE CORP自由现金流更多（$342.1M vs $-14.3M），过去两年AIR LEASE CORP的营收复合增速更高（69.6% vs 7.7%）
航空租赁公司（ALC）是2010年成立的美国飞机租赁企业，由史蒂文·F·乌德瓦-哈齐执掌运营。公司直接向波音、空客、巴航工业、ATR采购全新商用飞机，为全球各地航空公司客户提供专业的飞机租赁及融资服务。
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
AL vs APLS — 直观对比
营收规模更大
APLS
是对方的1.4倍
$140.8M
营收增速更快
AL
高出96.4%
-5.9%
净利率更高
AL
高出158.0%
-29.5%
自由现金流更多
AL
多$356.4M
$-14.3M
两年增速更快
AL
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $140.8M | $199.9M |
| 净利润 | $180.9M | $-59.0M |
| 毛利率 | — | — |
| 营业利润率 | — | -25.6% |
| 净利率 | 128.5% | -29.5% |
| 营收同比 | 90.4% | -5.9% |
| 净利润同比 | 60.2% | -62.2% |
| 每股收益（稀释后） | $1.49 | $-0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALAPLS
| Q4 25 | $140.8M | $199.9M | ||
| Q3 25 | $44.5M | $458.6M | ||
| Q2 25 | $53.0M | $178.5M | ||
| Q1 25 | $92.9M | $166.8M | ||
| Q4 24 | $74.0M | $212.5M | ||
| Q3 24 | $65.0M | $196.8M | ||
| Q2 24 | $57.8M | $199.7M | ||
| Q1 24 | $49.0M | $172.3M |
净利润ALAPLS
| Q4 25 | $180.9M | $-59.0M | ||
| Q3 25 | $146.5M | $215.7M | ||
| Q2 25 | $385.2M | $-42.2M | ||
| Q1 25 | $375.8M | $-92.2M | ||
| Q4 24 | $112.9M | $-36.4M | ||
| Q3 24 | $104.0M | $-57.4M | ||
| Q2 24 | $102.9M | $-37.7M | ||
| Q1 24 | $107.9M | $-66.4M |
营业利润率ALAPLS
| Q4 25 | — | -25.6% | ||
| Q3 25 | — | 48.7% | ||
| Q2 25 | — | -18.6% | ||
| Q1 25 | — | -50.0% | ||
| Q4 24 | — | -12.3% | ||
| Q3 24 | — | -24.0% | ||
| Q2 24 | — | -14.7% | ||
| Q1 24 | — | -36.0% |
净利率ALAPLS
| Q4 25 | 128.5% | -29.5% | ||
| Q3 25 | 329.2% | 47.0% | ||
| Q2 25 | 726.9% | -23.6% | ||
| Q1 25 | 404.5% | -55.3% | ||
| Q4 24 | 152.7% | -17.1% | ||
| Q3 24 | 160.0% | -29.2% | ||
| Q2 24 | 178.2% | -18.9% | ||
| Q1 24 | 220.2% | -38.5% |
每股收益（稀释后）ALAPLS
| Q4 25 | $1.49 | $-0.40 | ||
| Q3 25 | $1.21 | $1.67 | ||
| Q2 25 | $3.33 | $-0.33 | ||
| Q1 25 | $3.26 | $-0.74 | ||
| Q4 24 | $0.83 | $-0.30 | ||
| Q3 24 | $0.82 | $-0.46 | ||
| Q2 24 | $0.81 | $-0.30 | ||
| Q1 24 | $0.87 | $-0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.4M | $466.2M |
| 总债务越低越好 | $19.7B | — |
| 股东权益账面价值 | $8.5B | $370.1M |
| 总资产 | $32.9B | $1.1B |
| 负债/权益比越低杠杆越低 | 2.33× | — |
8季度趋势，按日历期对齐
现金及短期投资ALAPLS
| Q4 25 | $466.4M | $466.2M | ||
| Q3 25 | $452.2M | $479.2M | ||
| Q2 25 | $454.8M | $370.0M | ||
| Q1 25 | $456.6M | $358.4M | ||
| Q4 24 | $472.6M | $411.3M | ||
| Q3 24 | $460.8M | $396.9M | ||
| Q2 24 | $454.1M | $360.1M | ||
| Q1 24 | $554.4M | $325.9M |
总债务ALAPLS
| Q4 25 | $19.7B | — | ||
| Q3 25 | $20.2B | — | ||
| Q2 25 | $20.3B | — | ||
| Q1 25 | $19.9B | — | ||
| Q4 24 | $20.2B | — | ||
| Q3 24 | $20.2B | — | ||
| Q2 24 | $19.7B | — | ||
| Q1 24 | $19.5B | $93.1M |
股东权益ALAPLS
| Q4 25 | $8.5B | $370.1M | ||
| Q3 25 | $8.3B | $401.2M | ||
| Q2 25 | $8.2B | $156.3M | ||
| Q1 25 | $7.9B | $164.2M | ||
| Q4 24 | $7.5B | $228.5M | ||
| Q3 24 | $7.7B | $237.1M | ||
| Q2 24 | $7.3B | $264.3M | ||
| Q1 24 | $7.2B | $266.7M |
总资产ALAPLS
| Q4 25 | $32.9B | $1.1B | ||
| Q3 25 | $33.4B | $1.1B | ||
| Q2 25 | $33.3B | $821.4M | ||
| Q1 25 | $32.4B | $807.3M | ||
| Q4 24 | $32.3B | $885.1M | ||
| Q3 24 | $32.2B | $901.9M | ||
| Q2 24 | $31.0B | $904.5M | ||
| Q1 24 | $30.9B | $831.9M |
负债/权益比ALAPLS
| Q4 25 | 2.33× | — | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | 2.47× | — | ||
| Q1 25 | 2.53× | — | ||
| Q4 24 | 2.68× | — | ||
| Q3 24 | 2.63× | — | ||
| Q2 24 | 2.69× | — | ||
| Q1 24 | 2.69× | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $414.1M | $-14.2M |
| 自由现金流经营现金流 - 资本支出 | $342.1M | $-14.3M |
| 自由现金流率自由现金流/营收 | 242.9% | -7.1% |
| 资本支出强度资本支出/营收 | 51.1% | 0.1% |
| 现金转化率经营现金流/净利润 | 2.29× | — |
| 过去12个月自由现金流最近4个季度 | $1.5B | $45.0M |
8季度趋势，按日历期对齐
经营现金流ALAPLS
| Q4 25 | $414.1M | $-14.2M | ||
| Q3 25 | $458.6M | $108.5M | ||
| Q2 25 | $473.6M | $4.4M | ||
| Q1 25 | $388.3M | $-53.4M | ||
| Q4 24 | $430.0M | $19.4M | ||
| Q3 24 | $461.9M | $34.1M | ||
| Q2 24 | $413.8M | $-8.3M | ||
| Q1 24 | $371.3M | $-133.0M |
自由现金流ALAPLS
| Q4 25 | $342.1M | $-14.3M | ||
| Q3 25 | $412.3M | $108.3M | ||
| Q2 25 | $427.1M | $4.4M | ||
| Q1 25 | $315.5M | $-53.4M | ||
| Q4 24 | $326.8M | $19.3M | ||
| Q3 24 | $369.8M | — | ||
| Q2 24 | $346.4M | $-8.4M | ||
| Q1 24 | $246.8M | $-133.3M |
自由现金流率ALAPLS
| Q4 25 | 242.9% | -7.1% | ||
| Q3 25 | 926.6% | 23.6% | ||
| Q2 25 | 806.0% | 2.5% | ||
| Q1 25 | 339.5% | -32.0% | ||
| Q4 24 | 441.8% | 9.1% | ||
| Q3 24 | 569.1% | — | ||
| Q2 24 | 599.5% | -4.2% | ||
| Q1 24 | 503.8% | -77.3% |
资本支出强度ALAPLS
| Q4 25 | 51.1% | 0.1% | ||
| Q3 25 | 104.1% | 0.0% | ||
| Q2 25 | 87.8% | 0.0% | ||
| Q1 25 | 78.4% | 0.0% | ||
| Q4 24 | 139.6% | 0.0% | ||
| Q3 24 | 141.7% | 0.0% | ||
| Q2 24 | 116.7% | 0.0% | ||
| Q1 24 | 254.3% | 0.2% |
现金转化率ALAPLS
| Q4 25 | 2.29× | — | ||
| Q3 25 | 3.13× | 0.50× | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 1.03× | — | ||
| Q4 24 | 3.81× | — | ||
| Q3 24 | 4.44× | — | ||
| Q2 24 | 4.02× | — | ||
| Q1 24 | 3.44× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AL
暂无分部数据
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
